|Assessment process complete
|Fluticasone furoate/ umeclidinium/ vilantero
|For the maintenance treatment of adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy™ Ellipta™ be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement; August 2018.